Alnylam Pharmaceuticals reported $2.06B in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 332.22M 29.22M Sep/2026
Agios Pharmaceuticals USD 77.59M 7.37M Sep/2026
Alnylam Pharmaceuticals USD 2.06B 550.49M Sep/2026
Amgen USD 23.23B 2.27B Sep/2026
Arrowhead Research USD 311.34M 27.99M Sep/2026
BioCryst Pharmaceuticals USD 195.83M 13.02M Sep/2026
BioMarin Pharmaceutical USD 1.6B 59.17M Sep/2026
Incyte USD 1.44B 125.72M Sep/2026
Ionis Pharmaceuticals USD 435.29M 119.65M Sep/2026
Moderna USD 2.03B 506M Sep/2026
Neurocrine Biosciences USD 984.6M 110.1M Sep/2026
Novartis USD 32.52B 1.15B Sep/2026
PTC Therapeutics USD 776.08M 5.01M Sep/2026
Regeneron Pharmaceuticals USD 6.2B 671.5M Sep/2026
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sanofi EUR 31.93B 1.92B Jun/2026
Sarepta Therapeutics USD 656.35M 153.44M Sep/2026
Takeda JPY 2.6T 161B Sep/2026
Tectonic Therapeutic USD 10.37M 2.59M Jun/2026
Ultragenyx Pharmaceutical USD 389M 38M Sep/2026
Vertex Pharmaceuticals USD 5B 1.06B Sep/2026
Xencor USD 76.27M 5.6M Sep/2026